Dermata Therapeutics, Inc. (DRMA) earnings
DRMA earnings moved a median of -0.97% by the close. Quarterly and annual DRMA reports and results, each read against the price at its own news timestamp. Back to the DRMA overview →
21 measured DRMA earnings events.
Where these DRMA earnings landedvs 21 measured DRMA earnings reactions
| Middle 50% of DRMA earnings reactions | -4.55% to +10.40% |
|---|---|
| Median reaction (to close) | -0.97% |
| Measured reactions | 21 |
Point-in-time · zero look-ahead
Half of the 21 DRMA earnings events with a measured close landed between -4.55% and +10.40%; 33% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the Second Quarter 2026 | Press release | -1.20% | +10.40% | |
| Form 10-Q Dermata Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | -1.20% | +10.40% | |
| Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the First Quarter 2026 | Press release | -0.81% | +0.00% | |
| Form 10-Q Dermata Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | -0.81% | +0.00% | |
| Form 10-K Dermata Therapeutics, For: Dec 31 | SEC filing · Form 10-K | -2.21% | -13.23% | |
| Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results | Press release | -7.03% | -9.27% | |
| Form 10-Q Dermata Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | -7.03% | -9.27% | |
| Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results | Press release | +1.68% | -7.04% | |
| Form 10-Q Dermata Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | +1.68% | -7.04% | |
| Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results | Press release | +0.01% | -0.97% | |
| Form 10-Q Dermata Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | +0.01% | -0.97% | |
| Form 10-K Dermata Therapeutics, For: Dec 31 | SEC filing · Form 10-K | -0.51% | +1.70% | |
| Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results | Press release | +0.00% | -3.33% | |
| Form 10-Q Dermata Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | +0.00% | -3.33% | |
| Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results | Press release | +2.33% | +21.86% | |
| Form 10-Q Dermata Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | +2.33% | +21.86% | |
| Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results | Press release | +9.91% | +12.07% | |
| Form 10-Q Dermata Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | +9.91% | +12.07% | |
| Form 10-K Dermata Therapeutics, For: Dec 31 | SEC filing · Form 10-K | -1.15% | -4.55% | |
| Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results | Press release | -2.00% | -3.02% | |
| Form 10-Q Dermata Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | -2.00% | -3.02% |
Keep exploring
More DRMA: analyst actions → · SEC filings → · DRMA overview →